Strategic Regimen Access Leverage established regulatory pathways like the FDA 505(b)(2) to expedite market entry for reformulated and repurposed medicines, presenting a compelling value proposition for payors and clinicians seeking faster access to safer, effective options.

Diversified Portfolio Capitalise on a broad development slate of 28 products with 25 value-added medicines and high-barrier generics, plus ongoing early-stage programs, offering multiple collaboration and co-development opportunities across regions and indications.

Partnership Opportunities Pursue alliances with large pharma and specialty companies, as evidenced by recent licensing and co-development deals, to accelerate commercialization of key assets such as Sotalol IV and Maxigesic IV in strategic markets worldwide.

North American & Global Reach Target expansion through international collaborations and regional licenses, especially given RedHill licensing activity and multi-region regulatory strategies, to optimize market access and scale distribution for reformulated products.

Clinical & Real-World Value Highlight proven or potential cost-of-illness reductions and non-opioid post-operative pain solutions, plus anticoagulant care adjuncts, to engage payors, clinicians, and hospital systems seeking value-based care and improved patient outcomes.